Dr Dimitrios Priftakis details
Telephone:
GMC/GDC number:
7656211
Specialisms:
PET-based radiotherapy planning
Targeted molecular radiotherapy in thyroid cancer
Professional background
Dr Dimitrios Priftakis has been a member of the medical team at the Institute of Nuclear Medicine since 2018.
His clinical practice includes a wide range of isotope-based imaging and therapeutic applications for various benign and malignant conditions, including oncologic PET imaging, cardiac PET imaging, PET-based radiotherapy planning and radionuclide therapies for thyroid cancer, prostate cancer and other rare cancers.
Research interests
PSMA tracers for prostate cancer
Clinical utility of PET-derived quantitative parameters
New radionuclide therapy tracers
Languages spoken
Greek
Publications
20 journals including:
Towards more accurate 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) imaging in active and latent tuberculosis. Priftakis D, Riaz S, Zumla A, Bomanji J. Int J Infect Dis. 2020 Mar;92S:S85-S90.
A phase II, open-label study to assess safety and management change using 68Ga-THP PSMA PET/CT in patients with high-risk primary prostate cancer or biochemical recurrence. A Afaq, H Payne, R Davda, J Hines, GJR Cook, M Meagher, D Priftakis et al. Journal of Nuclear Medicine 62 (12), 1727-1734
The impact of Ga-68 DOTATATE PET/CT imaging on management of patients with paragangliomas. Skoura E, Priftakis D, Novruzov F, Caplin ME, Gnanasegaran G, Navalkissoor S, Bomanji J. Nucl Med Commun. 2020 Feb;41(2):169-174.
Molecular radionuclide therapy-induced salivary gland toxicity: an unappreciated threat to patients’ quality of life? S Vöö, V Mercadante, S Riaz, S Algodayan, C Scott, D Priftakis et al. Nuclear Medicine Communications 45 (7), 547-549
Book chapters: PET-CT in treatment response evaluation, Osteoarthritis of the foot and ankle (in Clinical Atlas of Bone SPECT/CT)